Table 3.
Current standards for using tumor markers in the metastatic setting
| CA 15-3 CA 27.29 |
NCCN: Optional ASCO: For monitoring patients with metastatic disease during therapy in combination with diagnostic imaging, history, and exam. |
| CEA | NCCN: Optional ASCO: For monitoring patients with metastatic disease during active therapy in combination with diagnostic imaging, history, and exam. |
Adapted from NCCN Guidelines 3.2013 and ASCO Tumor Marker Guidelines (2007).